News

Bayer expands in Down Under
Enlarge image

BusinessGermany

Bayer expands in Down Under

09.08.2012 - Bayer CropScience expands its R&D in Australia by the establishment of a breeding centre for stress- and drought resistant GM wheat and rapeseed.

The Monheim-based arm of German agri-biotech giant Bayer AG plans to build a new breeding centre near Horsham (Western Victoria). Bayer’s €12m investment for the new centre aims at developing new wheat and rapeseed varieties with higher yields and productivity tailored to Australian conditions. Australia ranks as the 3rd largest exporter for wheat and the 2nd largest for oilseeds.

"With the demand for wheat and oilseeds growing worldwide, we drive our efforts towards producing new high-yielding varieties that are better able to withstand pests, diseases and able to thrive under environmental stresses like drought," said Dr. Mathias Kremer, Head of the BioScience business unit at Bayer CropScience. The investment is part of Bayer’s plan to expand its wheat breeding stations in Asia and Latin America, which include huge consumer markets for wheat.

Construction of the new breeding centre will start in the coming months with first local breeding programs expected to yield results for Australian farmers within the decade, according to Bayer CropScience.

Agribiotechnology is a stragic growth field for the company. According to current market estimates of Companies & Markets the global agri-biotech market was valued at US$13.7bn and is estimated to hit US$14.4bn by the end of this year. Growing at an compound annual growth rate (CGAR) of 11.4% the agri-biotech market is to reach a value of US$24.8bn by 2017. Asia-Pacific represents the fastest growing agri-biotech market with a CGAR of 14% until 2015. Transgenic seeds, developed by Bayer CropScience as one of the key market players, make up the bulk of the market.

http://www.european-biotechnology-news.com/news/news/2012-03/bayer-expands-in-down-under.html

R&DUKIreland

29.07.2016 GlaxoSmithKline has in-licensed Janssen’s anti-IL-33R monoclonal antibody for severe asthma. The British drugmaker is paying €208m up front for the mAb.

ResearchEUUK

27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ZEALAND PHARMA (DK)131.00 DKK10.08%
  • DIAMYD MEDICAL -B- (S)4.69 SEK8.56%
  • IPSEN (F)59.44 EUR6.68%

FLOP

  • MOLOGEN (D)2.05 EUR-10.87%
  • PHARMING (NL)0.22 EUR-8.33%
  • VALNEVA (F)2.40 EUR-4.38%

TOP

  • THERAMETRICS (CH)0.05 CHF66.7%
  • PROTHENA PLC (IE)55.41 USD50.8%
  • VERNALIS (UK)44.50 GBP35.9%

FLOP

  • MOLOGEN (D)2.05 EUR-30.5%
  • SANTHERA (CH)55.00 CHF-26.8%
  • NICOX (F)10.49 EUR-14.3%

TOP

  • KARO BIO (S)31.20 SEK1874.7%
  • NICOX (F)10.49 EUR455.0%
  • SAREUM HOLDINGS (UK)0.77 GBP234.8%

FLOP

  • BB BIOTECH (D)44.84 EUR-84.7%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.78 SEK-78.3%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 28.07.2016